A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Destiny Pharma
Ticker: DEST Exchange: AIM www.destinypharma.com

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Destiny Pharma 27 Sep 2021

New dermal collaboration on XF-73

Destiny Pharma has announced a new clinical programme that is planned to start in China, led by its...

Read more
Destiny Pharma 09 Sep 2021

H1 2021 interims: still on track

Destiny's interim H1 2021 financial results were an upbeat and extensive update on the clinical...

Read more
Destiny Pharma 02 Aug 2021

XF-73 data maturing, like a fine wine

Destiny have released additional endpoint analyses after the positive headline announcement of the...

Read more
Destiny Pharma 02 Jul 2021

A glaring differential in validation

Recent transactions and the introduction of a new Act of the US Congress are further advancing the...

Read more
Destiny Pharma 07 Jun 2021

Encouraging AGM and M3 updates

Destiny’s recent announcement on the progress on its lead asset NTCD-M3 maintains the momentum that...

Read more
Destiny Pharma 04 May 2021

M3: another gem in the portfolio

With the recent announcement of the positive Phase 2b clinical study of XF-73 in the prevention of...

Read more
Destiny Pharma 14 Apr 2021

What a difference a year makes

Destiny has transformed its position, both in fundamental terms and in share price strength. A year...

Read more
Webinar recording on Phase 2b study results

Webinar recording on Phase 2b study results

Destiny Pharma 31 Mar 2021
Destiny Pharma 29 Mar 2021

The best possible scenario

Destiny has announced the top-line results of its Phase 2b clinical study of XF-73 in the...

Read more
Destiny Pharma 06 Jan 2021

2021 starts well with XF-73 study fully recruited

Destiny has announced that the patient recruitment for its Phase 2b study, conducted under a US...

Read more
Interview with CEO, Neil Clark

Interview with CEO, Neil Clark

Destiny Pharma 11 Dec 2020
Destiny Pharma 27 Nov 2020

Competition for XF-73 moves aside, issue approved

Our previous note discussed Destiny’s acquisition of the Phase 3-ready NTCD M3 product for the...

Read more
  • 1 of 3 pages

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates